Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) ...

We want to deschedule, deschedule, deschedule," Stower stated, underscoring her concern that rescheduling cannabis may disproportionately benefit larger companies with pharmaceutical backgrounds.

Needham analyst Serge Belanger has maintained their neutral stance on COLL stock, giving a Hold rating on October 24. Serge Belanger has given ...

Fintel reports that on October 25, 2024, TD Cowen downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from ...

When assessing Regeneron Pharmaceuticals against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made: Regeneron Pharmaceuticals demonstrates a stronger financial ...

Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and ProductivityJackie Klecker Named ...

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage ...

th { background-color: #293a5a ... After thoroughly examining Regeneron Pharmaceuticals, the following trends can be inferred: The Price to Earnings ratio of 25.48 is 0.42x lower than the industry ...

Wang, who started his career as a tour guide in Shanghai, joined AstraZeneca in 2013 after a 16-year stint at the Swiss health care company Roche, where he entered the industry with no pharmaceutical ...

UTSA was selected for a new grant that will foster a partnership with Bristol Myers Squibb (BMS), an industry leader in ...

Collegium Pharmaceutical Inc (COLL) reports a 17% increase in total net product revenues and outlines strategic plans for growth in the ADHD market.

Rigel Pharmaceuticals, Inc. beats earnings expectations ... Next, I’d like to provide some background information on our ...